N

Natera

Makes genetic tests for clinical care

Director – Organ Health IVD Product Development

Biology & BiotechConfirmed live in the last 24 hours
Full-timeAustin, TX, USA$185k - $231.2kIn-person

About the Job

Requirements

  • An advanced degree (PhD, MD, or equivalent) in Molecular Biology, Biomedical Engineering, Life Sciences, or a related field is required; an MS with additional relevant industry experience will be considered.
  • At least 6 years of experience in IVD or diagnostic device development under design controls is required.
  • At least 5 years of experience directing scientific or technical teams is required.
  • Deep technical expertise with complex NGS-based diagnostic assays, including assay design, analytical validation, and transfer to a commercial laboratory or manufacturing, is required.
  • Demonstrated direct experience in FDA interactions, such as Pre-Submission meetings, for a molecular diagnostic or NGS-based device is required.
  • Experience in molecular diagnostics for germline-based assays (SNVs, indels, and CNVs) is required.
  • Working knowledge of FDA premarket pathways for high-complexity IVD approvals is required.
  • Deep knowledge of FDA regulations (21 CFR Part 820/QMSR, Part 809, and Part 814), ISO 13485:2016, ISO 14971, and IVDR is required.
  • Demonstrated experience building and developing high-performing teams, including managers and senior scientists, and driving execution across functions in a matrixed organization, is required.
  • A strong understanding of germline-based assay diagnostics, design-controlled product development, and clinical validation, including analytical performance characterization of NGS assays, is required.

Responsibilities

  • Own the execution of the technical strategy and phase-gated process for development, design verification, and validation studies for next-generation sequencing (NGS)-based IVD devices that characterize germline mutations, including SNVs, indels, and CNVs, and serve as companion diagnostic (CDx) assays.
  • Ensure rigorous compliance with applicable FDA Class III (PMA) design and development requirements.
  • Own the analytical performance strategy, including accuracy, precision, interference, and stability, for germline assays, partnering directly with Regulatory Affairs, biostatistics, bioinformatics, and research teams.
  • Contribute to the transfer of assays to the commercial laboratory and manufacturing in support of design transfer and operations teams.
  • Partner with clinical and biostatistics leaders on statistical analysis plans required for approvable device performance claims in clinical intended-use populations.
  • Partner across bioinformatics, biostatistics, software engineering, clinical, regulatory, and commercial functions to align development efforts with business goals, and drive resourcing and go/no-go recommendations at phase gates.
  • Deliver the analytical performance data package supporting regulatory submissions and develop a comprehensive approval strategy with Regulatory Affairs.
  • Serve as the technical subject matter expert in correspondence and meetings with the FDA and pharma partners, defending performance evidence using data.
  • Apply Quality Management System requirements and regulatory guidance as the foundation of product development, including ISO 13485:2016, FDA QMSR 21 CFR Part 820, ISO 14971, and IEC 62304.
  • Build, develop, and retain a high-performing organization of scientists and managers, optimizing program budgets and external vendor partnerships.
  • Use data to identify technical and timeline risks, including ISO 14971 risk management deliverables, and make risk-based decisions on mitigation and escalation.

Desired Qualifications

  • Served as a principal technical contributor on a PMA, De Novo, or Breakthrough Device submission for an NGS-based germline assay.
  • Experience using multiple clinical trial assays (CTAs) for patient enrollment and later bridging to the final IVD candidate using clinical bridging studies.
  • Experience translating Laboratory Developed Tests (LDTs) into FDA-regulated IVD products.
  • Experience with bioinformatics pipelines and companion software as components of a regulated IVD under IEC 62304.
  • Experience developing and validating orthogonal tests, such as Sanger sequencing, qPCR, ddPCR, and MLPA, to validate NGS accuracy in challenging regions of the genome.

About the Company

Natera

Makes genetic tests for clinical care

Natera develops genetic tests for clinicians caring for people with cancer, inherited conditions, pregnancies, and organ transplants, using DNA analysis to inform medical decisions. Its portfolio includes Signatera for tracking residual cancer, Panorama for prenatal screening, and Prospera for assessing transplanted organ health. The company combines laboratory analysis with software that distinguishes DNA fragments in blood, and earns revenue mainly from diagnostic testing, alongside licensing and services for research partners. Clinicians use its portals to order tests, track samples, and review results, while patients have access to genetic information sessions. Natera was founded in 2004 and is headquartered in Austin, Texas.

Company size
5,001-10,000
Company stage
IPO
Headquarters
Austin, TX
Founded
2004

Recently Posted Jobs

Explore more opportunities at Natera

See more jobs